MktsMarkets

Moleculin Biotech, Inc.
NASDAQ: MBRXKey statistics
MBRX News
Stories mentioning MBRX from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 5,378 | 5,118 | 3,738 | 3,600 | 3,435 | 4,455 | 4,932 | 4,090 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 7,874 | 7,534 | 5,906 | 5,720 | 5,943 | 6,644 | 7,135 | 6,185 |
| Operating Income (Loss) | (7,874) | (7,534) | (5,906) | (5,720) | (5,943) | (6,644) | (7,135) | (6,185) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | 76.00 | (49.00) | 16.00 | 4.00 | 9.00 | 12.00 | 9.00 | 11.00 |
| Pretax Income | ||||||||
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income (Loss) | (12,845) | 15,552 | (25,399) | (17,809) | (5,904) | (6,584) | (7,024) | (6,015) |
| Earnings Per Share (Basic) | (3.54) | 13.12 | (0.68) | (1.15) | (15.80) | (47.71) | (1.89) | (2.37) |
| Earnings Per Share (Diluted) | ||||||||
| Weighted Average Shares Outstanding (Basic) | 4,124 | 1,185 | 37,304 | 15,526 | 374.00 | 138.00 | 3,714 | 2,543 |
| Weighted Average Shares Outstanding (Diluted) | ||||||||
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About MBRX
Moleculin Biotech, Inc. (NASDAQ: MBRX) is a stock listed on the Nasdaq Stock Market under the ticker symbol MBRX. It last traded at $7.37 (Oct 27, 2026, 10:04 AM ET), up 4.0% on the day. That gives Moleculin Biotech a market capitalisation of $7.2M.
Over the past 52 weeks MBRX has traded between $3.23 and $315.00.
Revenue for the quarter ended Mar 31, 2026 was $0; a net loss of $12.8M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | $0 | -$12.8M |
| Dec 31, 2025 | $0 | $15.6M |
| Sep 30, 2025 | $0 | -$25.4M |
| Jun 30, 2025 | $0 | -$17.8M |
From Moleculin Biotech’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…